Why Guidelines Stopped Recommending Aspirin for Most Healthy Adults

Guidelines stopped recommending routine daily aspirin for most healthy adults because a wave of large randomized trials showed the same thing: in people who have never had a heart attack or stroke, aspirin's protection against clots is modest and is largely offset by extra bleeding. In 2022 the U.S. Preventive Services Task Force recommended against starting aspirin for primary prevention at age 60 and older, and downgraded it to an individual decision for adults 40 to 59 with elevated cardiovascular risk. This reversed decades of near-reflexive advice. It did not change the separate, stronger case for aspirin in people who already have established cardiovascular disease.

This piece is educational and is not medical advice; decisions about starting or stopping aspirin belong with a person and their own clinician.

Two different questions hiding under one pill

The word "prevention" covers two very different situations, and conflating them is the root of most confusion about aspirin.

Secondary prevention means someone has already had a cardiovascular event, or has diagnosed disease such as a prior heart attack, ischemic stroke, or a stent. Their baseline risk of another event is high, so a treatment that lowers relative risk translates into a large absolute payoff.

Primary prevention means someone has no known cardiovascular disease. Their baseline risk is lower, so the same relative benefit yields a much smaller absolute one, while the bleeding harm stays roughly constant. That asymmetry is the entire story.

The Antithrombotic Trialists' Collaboration meta-analysis, published in The Lancet in 2009, laid this out with individual-patient data. In secondary prevention, aspirin produced roughly a 19 percent proportional reduction in serious vascular events, an absolute benefit near 1.5 percent per year. In primary prevention, the proportional reduction was smaller, near 12 percent, the absolute benefit was on the order of hundredths of a percent per year, and major gastrointestinal and other extracranial bleeds rose by about half. The authors concluded that for healthy people the net value was uncertain. That uncertainty is what later trials were built to resolve.

What the newer trials showed

Between 2016 guidance and the 2022 revision, three large randomized trials reported, and they pointed the same direction.

ASCEND studied more than 15,000 adults with diabetes but no known cardiovascular disease. Aspirin did lower serious vascular events, but the reduction was closely matched by an increase in major bleeding, so the net gain was marginal.

ARRIVE enrolled adults judged to be at moderate risk. In practice their event rates came in lower than expected, and aspirin failed to reduce cardiovascular events while increasing gastrointestinal bleeding.

ASPREE tested low-dose aspirin in more than 19,000 community-dwelling adults aged 70 and older who were healthy at entry. Aspirin did not prolong disability-free survival and did not meaningfully reduce first heart attacks or strokes. It did significantly increase major hemorrhage, and all-cause mortality was slightly higher in the aspirin group, an excess linked largely to cancer deaths and still debated. For an ostensibly protective drug, a signal pointing the wrong way on mortality is a serious finding.

None of these trials claimed aspirin does nothing to platelets. They showed that in lower-risk people the arithmetic of benefit versus harm does not favor routine use.

Reading the tradeoff honestly

The clean way to think about this is absolute risk, not relative risk. A "30 percent reduction" sounds decisive until you attach it to a baseline. Cut a 1-in-1000 yearly risk by a third and you prevent roughly 3 events per 10,000 people per year. If aspirin simultaneously causes a comparable number of serious bleeds, the ledger nets close to zero, and some people are simply trading a prevented clot for a caused hemorrhage.

Two features tilt the ledger further. First, bleeding harm is not flat across age. The USPSTF notes that the absolute incidence of bleeding, and therefore the magnitude of harm, rises with age, which is exactly why the 2022 statement draws its firmest line at 60 and older. Second, background cardiovascular care has improved. Widespread statin use, blood-pressure treatment, and lower smoking rates have pushed baseline event rates down, shrinking the room aspirin has to help. A drug tested against 1980s baseline risk is being asked to work against a healthier 2020s baseline.

What the 2022 recommendation actually says

The USPSTF 2022 statement is more specific than the headlines suggest. For adults aged 40 to 59 with a 10-year cardiovascular risk of 10 percent or greater, it calls the decision to start low-dose aspirin an individual one, a Grade C, meaning any net benefit is small and depends on personal factors including bleeding risk and preference. For adults 60 and older, it recommends against initiating aspirin for primary prevention, a Grade D. That is a notable step down from the 2016 guidance, which had carried a Grade B endorsement for a portion of this population.

Two boundaries matter. The statement addresses starting aspirin, not a blanket order to stop it, and it explicitly excludes people with elevated bleeding risk from the group who might consider it. It is a framework for shared decisions, not a universal rule.

Why secondary prevention did not move

For people with established cardiovascular disease, the evidence base did not weaken, and guidance for them was not reversed. Their high baseline risk means the same antiplatelet effect prevents far more events in absolute terms, so the benefit continues to outweigh the bleeding cost for most. This is the case appraised in the ATT secondary-prevention data and reaffirmed in cardiology guidance. The lesson is not that aspirin is weak. It is that the same drug lands differently depending on who takes it, which is what evidence-based prevention is supposed to capture.